Clin2
NCT07536308Possibly a fitRecruiting

Nasal COVID-19 booster vaccine safety trial

COVID-19

Part of Infections, Lungs & breathing clinical trials.

This trial tests a new nasal spray COVID-19 booster vaccine. It aims to see if the vaccine is safe and produces a strong immune response when given through the nose and inhaled, in people who have already been vaccinated.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
80 people
Ages
18 years to 64 years
Study type
Interventional

Who can take part

  • You are 18 to 64 years old and in good general health.
  • You have already received a complete COVID-19 vaccine series and at least one booster, with the last dose at least 16 weeks ago.
  • You do not have any lung, nose, or sinus disease that requires daily medication.
  • You have not smoked or used any nicotine products (including vaping) in the last 3 months.
  • You are willing to use effective birth control (if applicable) and not get pregnant or breastfeed during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06768697Not yet recruiting· Early Phase 1
Nasal spray COVID-19 booster shot study

This trial tests a nasal spray booster for people who have already had 2-3 doses of COVID-19 inactivated vaccine. It studies if the spray is safe and boosts your immune system. You can join if you are healthy, have not had COVID-19 in the last 3 months, and had your last vaccine dose more than 6 months ago.

Shanghai, Jinshan District
NCT07703475Not yet recruiting· Phase 1
Booster nasal spray COVID-19 vaccine safety study

This trial tests a new nasal spray booster for COVID-19 in adults 18–64 who have already had a primary vaccine series and at least one booster. The goal is to see if it is safe and triggers a good immune response.

New York, New York
NCT05787418Enrolling by invitation· Phase 3
Nasal spray to prevent COVID-19 after a close exposure

This Phase 3 trial tests whether a medicated nasal spray can stop COVID-19 from starting after you’ve been exposed to someone who recently tested positive. You must start very soon after the person became symptomatic, and you’ll be checked for eligibility based on timing and your health history.

Beijing
NCT06810934Recruiting· Phase 1/Phase 2
New COVID-19 vaccine study for those with prior mRNA vaccines

This study tests a new type of COVID-19 vaccine that is designed to train your immune system to make stronger, longer-lasting protection. You may be able to join if you are 40–64, have already had at least two doses of a mRNA COVID-19 vaccine (Pfizer or Moderna) more than 4 months ago, and are generally healthy.

Los Angeles, California
NCT06255626Recruiting· Phase 1/Phase 2
New COVID-19 booster vaccine study

This trial tests a new type of COVID-19 booster vaccine that targets a protein to help your immune system. It's for people who already had a primary vaccine series and at least one mRNA booster, with the last booster at least 6 months ago.

Créteil
NCT05911061Not yet recruiting· Phase 3
Booster shot study for COVID-19 in adults

This Phase 3 trial tests a booster vaccine made from a three-part COVID-19 protein (aimed at XBB, BA.5, and Delta) to see how well it works and is tolerated. It may help adults who are due for a COVID-19 booster, including people with certain health conditions, depending on screening results.

Hear when a new COVID-19 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.